Agilent Technologies has annouced a strategic collaboration with PharmiGENE, a global leader in pharmacogenetics based in Taiwan, to establish a high-end cell analysis research platform at the latter’s Research and Development Center (the Center). By applying Agilent NovoCyte Opteon, the company’s new spectral flow cytometry system, PharmiGENE aims to enhance the Center’s biomedical research and analysis capabilities.

 

Unveiled in May 2024, the Agilent NovoCyte Opteon spectral flow cytometer represents a significant leap forward in flow cytometry technology, featuring the configurations of multi detectors that supports high-quality analyzing. It sets a new standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development. Since its release, Agilent NovoCyte Opteon has been highlighted by the market and has won double-digit orders. PharmiGENE is also the first company in the world to order this new product.

 

Collaborated with regional distributor Level Biotechnology Inc., PharmiGENE has installed the Agilent NovoCyte Opteon spectral flow cytometer system, combined with other advanced cell analysis solutions, e.g., Agilent Seahorse cell energy metabolic analyzer and Agilent BioTek Cytation C10 confocal imaging reader, to create a powerful comprehensive cell analysis platform, which will help PharmiGENE achieve additional research breakthroughs in the fields of cancer companion testing and regenerative medicine.

 

 

Dr. YU-ZHEN HUANG, Director of R&D Center at PharmiGENE, emphasized the importance of this collaboration: “Our cooperation with Agilent and Level Biotechnology will bring new opportunities for our innovation and technological breakthroughs. We look forward to advancing our capacity in precision testing and regenerative medicine to bring new hope to patients, and to consolidating our position in the global regenerative medicine industry.”

 

Dr. LI Jian, Associate Vice President, General Manager of DGG greater China sales at Agilent, commented, “We are thrilled that PharmiGENE made world’s first order and adopted our innovative NovoCyte Opteon spectral flow cytometer. This remarkable milestone highlights the global impact of our cell analysis and flow cytometry technology. We eagerly anticipate the research achievements that will emerge from this collaboration, expanding the application areas of our comprehensive cell analysis solutions.”

 

A current research focus at PharmiGENE’s R&D Center is using mitochondrial polysomy as a platform for developing biomarkers in disease metabolic development processes and key functional testing of cell therapy products. Collaborating with medical institutions including National Taiwan University Hospital and others, PharmiGENE aims to ensure that its technologies and products are closely aligned with clinical needs. Looking ahead, PharmiGENE plans to develop clinical-related services.

 

 

About PharmiGENE

PharmiGENE was established in 2005 and funded by venture capitalists and angel investors. Our goal is to innovate and commercialize diagnostic tests that enable everyone to be better informed about his/her genetic makeup and to make decisions that can better their health. We have licensed from Academia Sinica the exclusive rights to key technologies relating to genetic markers associated with adverse drug reactions caused by several popular pharmaceutical products. We have obtained ISO 13485 and GMP certifications and are manufacturing our DNA genetic tests under the most stringent guidelines. We also have validated our DNA genetic tests with clinical studies that involved hundreds and thousands of patients. Today, our DNA genetic tests are available worldwide, receiving IVD clearance from the Ministry of Health and Welfare of Taiwan. For more information, please visit pharmigene.com.tw.

 

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company-generated revenue of $6.85 billion in fiscal 2022 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

 

---

Media Inquiries

To request more information or learn more about the Agilent NovoCyte Opteon spectral flow cytometer please contact:
 
Agilent Business Public Relations
pdl-business-pr@agilent.com

---